Identification of F5 as a Prognostic Biomarker in Patients with Gastric Cancer

• Published in: BioMed research international Vol. 2020; no. 2020; pp. 1 - 13
• Main Authors: Mo, Xian-Wei, Qin, Yu-Zhou, Liao, Xiwen, Liu, Yi, Luo, Shan-Shan
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Accuracy; Analysis; Biomarkers; Cancer; Cancer patients; Cancer therapies; Care and treatment; Coagulation; Coagulation factors; Datasets; Factor V; Gastric cancer; Gene expression; Gene sequencing; Genes; Genetic aspects; Genomes; Genomics; Levels; Medical prognosis; Medical research; Medicine, Experimental; mRNA; Plotters; Prognosis; Radiation therapy; RNA; Software; Stomach cancer; Survival; Survival analysis; Tumors; China; Taiwan
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2020/9280841

Association of Coagulation factor V (F5) polymorphisms with the occurrence of many types of cancers has been widely reported, but whether it is of prognostic relevance in some cancers remain to be resolved. The RNA-sequencing dataset was downloaded from The Cancer Genome Atlas (TCGA). The potential of F5 genes to predict the survival time of gastric cancer (GC) patients was investigated using univariate and multivariate survival analysis whereas “Kaplan-Meier plotter” (KM-plotter) online tools were employed to validate the outcomes. TCGA data revealed that F5 mRNA levels were significantly upregulated in gastric cancer samples. Survival analysis confirmed that high levels of F5 mRNA correlated with short overall survival (OS) in gastric cancer patients, and the area under the curve (AUC) values of 1-, 2-, and 5-year OS rate were 0.554, 0.593, and 0.603, respectively. Survival analysis by KM-plotter indicated that the high expression of F5 mRNA was significantly associated with a shorter OS compared with the low expression level in all patients with GC, and this was also the case for patients in stage III (hazard ratio HR=1.78, P=0.017). These findings suggest that the F5 gene is significantly upregulated in GC tumour tissues, and may be a potential prognostic biomarker for GC.